© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
April 12, 2021
A study finds low risk of malignancy from secukinumab treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis patients, despite limited data.
A recent study finds increasing number of women with PsA, but an overall stable incidence of disease compared to previous studies in same population.
June 17, 2020
The approval is based on the phase 3 PREVENT trial, presented at the European E-Congress of Rheumatology 2020 (EULAR 2020) virtual meeting.
June 06, 2020
Study drug also recently showed promise in treating psoriatic arthritis.
June 01, 2020
The sBLA indication is the fifth for the IL17A inhibitor, which showed reduction of inflammatory signs and symptoms in treated patients at 52 weeks.
December 12, 2019
How therapies are advancing treat-to-target strategies, while the field faces a physician shortage issue.
November 14, 2019
Aileen Pangan, MD, executive medical director of Immunology with AbbVie, discusses the results of the SELECT-AXIS 1 trial and what it indicates about upadacitinib as a treatment for ankylosing spondylitis.
November 13, 2019
Deodhar discusses the results of a study comparing the symptoms and treatment patterns in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.
October 02, 2019
Novartis announced the ongoing Phase 3 PREVENT trial examining use of secukinumab in patients with non-radiographic axial spondyloarthritis has met its primary endpoint of ASAS40.
September 29, 2019
A 12-week phase 2 study comparing filgotinib to placebo found the oral, selective JAK1-inhibitor could be an effective treatment for ankylosing spondylitis.